Literature DB >> 3718806

A simple borohydride/GC method for measuring sparteine metabolites in man.

T Inaba, A Vinks, S V Otton.   

Abstract

A simple borohydride/GC method was developed for phenotyping sparteine oxidation in man. The major metabolites of sparteine found in human urine, 2- and 5-dehydrosparteine, were converted quantitatively back to sparteine by sodium borohydride reduction. The amount of sparteine metabolites can be estimated from the difference of sparteine concentrations between the borohydride-treated and untreated urine samples. The coefficient of variation of this assay was estimated from repeated analyses to be +/- 3% within a day (intra-assay) and +/- 8% between days (inter-assay).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3718806      PMCID: PMC1401017          DOI: 10.1111/j.1365-2125.1986.tb02828.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation.

Authors:  G Alvan; C von Bahr; P Seidemann; F Sjöqvist
Journal:  Lancet       Date:  1982-02-06       Impact factor: 79.321

2.  Comparative pharmacogenetics of sparteine and debrisoquine.

Authors:  T Inaba; A Vinks; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

Review 3.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

4.  In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine.

Authors:  S V Otton; T Inaba; W A Mahon; W Kalow
Journal:  Can J Physiol Pharmacol       Date:  1982-01       Impact factor: 2.273

5.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

6.  Oxidation phenotype--a major determinant of metoprolol metabolism and response.

Authors:  M S Lennard; J H Silas; S Freestone; L E Ramsay; G T Tucker; H F Woods
Journal:  N Engl J Med       Date:  1982-12-16       Impact factor: 91.245

7.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

8.  Deficient metabolism of debrisoquine and sparteine.

Authors:  T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1980-04       Impact factor: 6.875

9.  Sparteine metabolism in Canadian Caucasians.

Authors:  A Vinks; T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

10.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.